| Autor: |
Mathews JA; Ionis Pharmaceuticals, 2855 Gazelle Rd., Carlsbad, California, 92010, USA. jmathews@ionisph.com., Ni YG; Regeneron, Tarrytown, New York, USA., Wang C; Novartis, Cambridge, Massachusetts, USA., Peterson JE; Bristol-Myers Squibb, Princeton, New Jersey, USA., Ray C; Zoetis, Kalamazoo, Michigan, USA., Zhao X; Merck & Co., Kenilworth, New Jersey, USA., Duan D; Regeneron, Tarrytown, New York, USA., Hamon S; Regeneron, Tarrytown, New York, USA., Allinson J; Immunologix Laboratories, Tampa, Florida, USA., Hokom M; Genentech, South San Francisco, California, USA., Wegner G; R&D Systems, Minneapolis, Minnesota, USA. |
| Abstrakt: |
Blood-based soluble protein biomarkers provide invaluable clinical information about patients and are used as diagnostic, prognostic, and pharmacodynamic markers. The most commonly used blood sample matrices are serum and different types of plasma. In drug development research, the impact of sample matrix selection on successful protein biomarker quantification is sometimes overlooked. The sample matrix for a specific analyte is often chosen based on prior experience or literature searches, without good understanding of the possible effects on analyte quantification. Using a data set of 32 different soluble protein markers measured in matched serum and plasma samples, we examined the differences between serum and plasma and discussed how platelet or immune cell activation can change the quantified concentration of the analyte. We have also reviewed the effect of anticoagulant on analyte quantification. Finally, we provide specific recommendations for biomarker sample matrix selection and propose a systematic and data-driven approach for sample matrix selection. This review is intended to raise awareness of the impact and considerations of sample matrix selection on biomarker quantification. |
Full text from SpringerLink